Market news
Detailed price information for Foghorn Therapeutics Inc (FHTX-Q) from The Globe and Mail including charting and trades.
The consensus price target hints at a 67% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Detailed price information for Foghorn Therapeutics Inc (FHTX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Foghorn Therapeutics Inc (FHTX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Foghorn Therapeutics Inc (FHTX-Q) from The Globe and Mail including charting and trades.
- FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population - Selective EP300 degraders with potential to treat multiple myeloma and other hematological malignancies advancing; IND targeted in 2027 - Accelerating a novel oral small molecule in immunology and inflammation toward IND in 2027 - Strong balance sheet with cash, cash equivalents, and marketable securities of approximately $168 million; cash runway in
Foghorn Therapeutics (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
This is the newest page. Registered accounts read further back.